Dihydroergocryptine (DHEC, trade names Almirid, Cripar) is a dopamine agonist of the ergoline chemical class that is used as an antiparkinson agent. Dihydroergocryptine has been shown to be particularly effective as monotherapy in the early stages of Parkinson's disease. Initial monotherapy with a dopamine agonist (other examples include pergolide, pramipexole, and ropinirole) is associated with reduced risk for motor complications in Parkinson patients relative to levodopa. DHEC, like other dopamine agonists, aims to mimic the endogenous neurotransmitter and exert an antiparkinsonian effect. Recent evidence also supports that dopamine receptor agonists, instead of L-DOPA may slow or prevent the progression of Parkinson's disease.

CAS：25447-66-9
中文别名：
英文别名：Dihydroergokryptine;Dihydroergocryptine;EINECS 246-993-6;Dihydroergocriptine;dihydro-alpha-ergocryptine;
分子式：C32H43N5O5
分子量：577.714
精确质量：577.326
Psa：121.7
Logp：3.1746

UNII：202229IR8Y

密度：1.36g/cm3
沸点：848.7ºC at 760 mmHg
闪点：467.1ºC
折射率：1.667
蒸汽压：1.26E-30mmHg at 25°C